Application of compound sclerotiorin in preparing antituberculosis medicine

A compound and anti-tuberculosis technology, applied in the direction of antibacterial drugs, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve problems such as difficult to kill, slow bacterial growth, and reduced metabolic activities, and achieve low production costs and source Enrich, reduce proliferation effect

Inactive Publication Date: 2017-02-22
SUN YAT SEN UNIV
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The slow growth of bacteria and the protective effect of the cell wall, the bacteria can enter a dormant state when encountering adversity, the metabolic activity is reduced, and the growth almost stops, resisting the adverse growth environment of the outside world, not easy to be killed by antibacterial drugs, and can be latent in the host cell for a long time. make it difficult to completely eradicate tuberculosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound sclerotiorin in preparing antituberculosis medicine
  • Application of compound sclerotiorin in preparing antituberculosis medicine
  • Application of compound sclerotiorin in preparing antituberculosis medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 J774A.1 Intracellular Proliferation Experiment

[0037] When the adhesion and confluence of mouse alveolar macrophage J774A.1 reached 80%-90%, discard the medium and add preheated RPMI1640 medium to elute the non-adherent cells. Add 2 mL of RPMI1640 medium, collect the cells with a cell scraper, place them in a 15 mL centrifuge tube, and centrifuge at 1000 rpm for 3 minutes at room temperature. Discard the supernatant, and resuspend the cells with 1 mL of RPMI1640 medium containing 10% bovine serum. Take a small amount of resuspended cells, count the cells with a hemocytometer, and calculate the cell density. The density of the cell resuspension was adjusted to 1×10 with RPMI1640 medium containing 10% bovine serum 6 cells / mL, the diluted cells were dispensed into 6-well cell culture plates at 1 mL / well. Place the cell plate in 37°C CO 2 overnight in the incubator to allow the cells to fully adhere to the wall.

[0038] On the 7H11 plate, scrape the 2-3-we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a compound sclerotiorin in preparing antituberculosis medicine. Research discovers that the compound sclerotiorin can inhibit proliferation of mycobacterium tuberculosis in cells, the compound sclerotiorin is combined with rifampicin or isoniazide, proliferation of mycobacterium tuberculosis in macrophage can be effectively reduced, the compound sclerotiorin is a natural metabolic activity micromolecule product separated from marine microorganisms, the structure of the compound sclerotiorin is analyzed, the compound sclerotiorin can be produced through large-scale fermentation and separation, sources are rich, and the production cost is low; under treatment of the compound sclerotiorin of 40 microns and rifampicin of 0.025 mg/L, or under treatment of the compound sclerotiorin of 40 microns and isoniazide of 0. 05 mg/L, the number of the mycobacterium tuberculosis in cells is reduced by 84% and 45% respectively. The compound sclerotiorin has the clinical application potential for treating tuberculosis.

Description

technical field [0001] The present invention relates to the field of biotechnology, more specifically, relates to the application of compound sclerotiorin in the preparation of anti-tuberculosis drugs. Background technique [0002] Tuberculosis, a chronic infectious disease caused by the bacterium Mycobacterium tuberculosis, usually affects the lungs, and is one of the leading deadly infectious diseases worldwide. Tuberculosis occurs in various parts of the world, mainly concentrated in Asia, Africa and Latin America. About one-third of the world's population has latent tuberculosis. According to the World Health Organization 2015 Global Tuberculosis Control Report, in 2015, a total of 9.6 million people were infected with tuberculosis and 1.5 million people died of tuberculosis. Although in the past two decades, China's tuberculosis cases and death rate have continued to decline significantly, but China ranks third among the world's top ten tuberculosis-incidence countries...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61K31/4409A61K31/352A61P31/06
CPCA61K31/352A61K31/4409A61K31/496
Inventor 陆勇军陈冬妮佘志刚何磊袁培博
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap